Baseline characteristics based on SF3B1 MT
| . | Comparing all SF3B1 MT vs SF3B1 WT (n = 1729) . | Comparing SF3B1 MT pts based on new IWG proposal criteria (n = 320) . | ||||
|---|---|---|---|---|---|---|
| . | SF3B1 MT n = 320 . | SF3B1 WT n = 1409 . | P . | SF3B1 MT IWG (n = 175) . | SF3B1 MT non-IWG (n = 145) . | P . |
| Age (mean), y | 70 | 68.5 | .037 | 69 | 71 | .2 |
| Gender (male) | 62% | 64% | .55 | 67% | 56% | .04 |
| Race (white) | 94% | 90% | .13 | 96% | 92% | .38 |
| t-MDS | 9% | 17% | .001 | 10% | 9% | .7 |
| WHO 2016 | <.005 | <.005 | ||||
| MDS-SLD | 3% | 9% | 5% | 1% | ||
| MDS-MLD | 8% | 26% | 8% | 8% | ||
| MDS-SLD-RS | 31% | 1% | 48% | 11% | ||
| MDS-MLD-RS | 25% | 3% | 37% | 9% | ||
| MDS-EB-1 | 6% | 17% | 0 | 13% | ||
| MDS-EB-2 | 6% | 21% | 0 | 12% | ||
| MDS-U | 1% | 2% | 1% | 1% | ||
| AML | 2% | 12% | 0 | 5% | ||
| MDS/MPN | 3% | 5% | 0 | 8% | ||
| del(5q) | 2% | 4% | 0 | 4% | ||
| MDS/MPN-RS-T | 13% | 0 | 0 | 28% | ||
| IPSS-R | <.005 | <.005 | ||||
| Very low | 28% | 10% | 35% | 18% | ||
| Low | 52% | 25% | 61% | 43% | ||
| Intermediate | 10% | 21% | 4% | 17% | ||
| High | 5% | 19% | 0 | 11% | ||
| Very high | 5% | 25% | 0 | 11% | ||
| AML transformation | 12.5% | 38% | <.005 | 4.7% | 22% | <.005 |
| Myeloblasts | 3.2% | 8% | <.005 | 1.5% | 5% | <.005 |
| Hgb (g/dL) | 11.3 | 9.7 | .007 | 12.9 | 9.0 | .2 |
| ANC | 3.5 | 2.4 | .008 | 2.8 | 4.3 | .01 |
| Platelets | 287 | 129 | <.005 | 242 | 341 | <.005 |
| Mutation landscape | ||||||
| TET-2 | 31% | 21% | <.005 | 33% | 28% | .5 |
| DNMT3A | 21% | 13% | <.005 | 21% | 21% | .96 |
| ASXL-1 | 15% | 22% | <.005 | 11% | 19% | .15 |
| IDH-1 | 1.9% | 3.3% | .001 | 1% | 3% | .5 |
| IDH-2 | 2% | 5% | <.005 | 2% | 2% | .9 |
| SRSF2 | 4% | 13% | <.005 | 3% | 6% | .3 |
| U2AF1 | 1.6% | 12% | <.005 | 1% | 1% | .7 |
| ZRSR2 | 5% | 6% | .001 | 1% | 1% | .6 |
| EZH-2 | 5% | 7.5% | <.005 | 0 | 11% | <.005 |
| RUNX-1 | 12% | 9% | .001 | 0 | 21% | <.005 |
| ETV-6 | 1.6% | 4% | .007 | 2% | 1% | .9 |
| TP53 | 4.7% | 21% | <.005 | 0 | 10% | <.005 |
| CBL | 1.9% | 3% | .007 | 2% | 2% | .9 |
| NRAS | 1.9% | 3.8% | <.005 | 1% | 3.4% | .2 |
| SETBP1 | 3.8% | 4.3% | .1 | 3.5% | 4% | .9 |
| JAK-2 | 8.5% | 3.4% | <.005 | 6% | 12% | .16 |
| MPL | 2.2% | 1.2% | .026 | 2% | 1% | .8 |
| . | Comparing all SF3B1 MT vs SF3B1 WT (n = 1729) . | Comparing SF3B1 MT pts based on new IWG proposal criteria (n = 320) . | ||||
|---|---|---|---|---|---|---|
| . | SF3B1 MT n = 320 . | SF3B1 WT n = 1409 . | P . | SF3B1 MT IWG (n = 175) . | SF3B1 MT non-IWG (n = 145) . | P . |
| Age (mean), y | 70 | 68.5 | .037 | 69 | 71 | .2 |
| Gender (male) | 62% | 64% | .55 | 67% | 56% | .04 |
| Race (white) | 94% | 90% | .13 | 96% | 92% | .38 |
| t-MDS | 9% | 17% | .001 | 10% | 9% | .7 |
| WHO 2016 | <.005 | <.005 | ||||
| MDS-SLD | 3% | 9% | 5% | 1% | ||
| MDS-MLD | 8% | 26% | 8% | 8% | ||
| MDS-SLD-RS | 31% | 1% | 48% | 11% | ||
| MDS-MLD-RS | 25% | 3% | 37% | 9% | ||
| MDS-EB-1 | 6% | 17% | 0 | 13% | ||
| MDS-EB-2 | 6% | 21% | 0 | 12% | ||
| MDS-U | 1% | 2% | 1% | 1% | ||
| AML | 2% | 12% | 0 | 5% | ||
| MDS/MPN | 3% | 5% | 0 | 8% | ||
| del(5q) | 2% | 4% | 0 | 4% | ||
| MDS/MPN-RS-T | 13% | 0 | 0 | 28% | ||
| IPSS-R | <.005 | <.005 | ||||
| Very low | 28% | 10% | 35% | 18% | ||
| Low | 52% | 25% | 61% | 43% | ||
| Intermediate | 10% | 21% | 4% | 17% | ||
| High | 5% | 19% | 0 | 11% | ||
| Very high | 5% | 25% | 0 | 11% | ||
| AML transformation | 12.5% | 38% | <.005 | 4.7% | 22% | <.005 |
| Myeloblasts | 3.2% | 8% | <.005 | 1.5% | 5% | <.005 |
| Hgb (g/dL) | 11.3 | 9.7 | .007 | 12.9 | 9.0 | .2 |
| ANC | 3.5 | 2.4 | .008 | 2.8 | 4.3 | .01 |
| Platelets | 287 | 129 | <.005 | 242 | 341 | <.005 |
| Mutation landscape | ||||||
| TET-2 | 31% | 21% | <.005 | 33% | 28% | .5 |
| DNMT3A | 21% | 13% | <.005 | 21% | 21% | .96 |
| ASXL-1 | 15% | 22% | <.005 | 11% | 19% | .15 |
| IDH-1 | 1.9% | 3.3% | .001 | 1% | 3% | .5 |
| IDH-2 | 2% | 5% | <.005 | 2% | 2% | .9 |
| SRSF2 | 4% | 13% | <.005 | 3% | 6% | .3 |
| U2AF1 | 1.6% | 12% | <.005 | 1% | 1% | .7 |
| ZRSR2 | 5% | 6% | .001 | 1% | 1% | .6 |
| EZH-2 | 5% | 7.5% | <.005 | 0 | 11% | <.005 |
| RUNX-1 | 12% | 9% | .001 | 0 | 21% | <.005 |
| ETV-6 | 1.6% | 4% | .007 | 2% | 1% | .9 |
| TP53 | 4.7% | 21% | <.005 | 0 | 10% | <.005 |
| CBL | 1.9% | 3% | .007 | 2% | 2% | .9 |
| NRAS | 1.9% | 3.8% | <.005 | 1% | 3.4% | .2 |
| SETBP1 | 3.8% | 4.3% | .1 | 3.5% | 4% | .9 |
| JAK-2 | 8.5% | 3.4% | <.005 | 6% | 12% | .16 |
| MPL | 2.2% | 1.2% | .026 | 2% | 1% | .8 |
Number of somatic mutations tested using the standard Illumina platform, 70% included ≥54 gene panels with a minimum 13-gene panel.
ANC, absolute neutrophil count; Hgb, hemoglobin; MDS-U, MDS-unclassified; MPN, myeloproliferative neoplasm; pts, patients; RS-T, RS with thrombocytosis; WHO, World Health Organization.